Liver Disease
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 62/701,309, filed Jul 20, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,097,207 | Liver Disease In force · Medium confidence | Lipocine, Inc. | In force | Medium confidence | ||
| US 12,150,945 | Liver Disease In force · Medium confidence | Lipocine Inc. | In force | Medium confidence | ||
| US 11,931,367 | Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate Therapy In force · High confidence | Lipocine, Inc. | In force | High confidence | ||
| US 12,156,881 | Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate Therapy In force · High confidence | Lipocine Inc. | In force | High confidence | ||
| US 12,318,396 | Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate Therapy In force · Low confidence | Lipocine, Inc. | In force | Low confidence | ||
| Application 16/554,444 | Liver Disease Pending Not granted | Lipocine Inc. | Pending | Not granted | ||
| Application 17/001,813 | Liver Disease Abandoned Abandoned Oct 21, 2025 | Lipocine, Inc. | Abandoned | Abandoned Oct 21, 2025 | ||
| Application 17/001,855 | Liver Disease Abandoned Abandoned Jul 31, 2024 | Lipocine, Inc. | Abandoned | Abandoned Jul 31, 2024 | ||
| Application 18/437,438 | Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate Therapy Abandoned Abandoned Sep 12, 2025 | Lipocine Inc. | Abandoned | Abandoned Sep 12, 2025 |
9 of 9 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Lipocine Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.